Latest News & Views in Diabetes Technology

The tubeless Accu-Chek Solo micropump system from Roche has gained FDA approval, providing a new insulin delivery solution for individuals aged 2 years and older with type 1 diabetes.

Tandem Diabetes Care announced a tech access program to give t:slim X2 customers a purchase pathway to the tandem mobi system for $199.

ADCES 2023 is full of amazing educational sessions, exhibitors, and opportunities for hands-on learning with a tech focus and since I don’t want to bury the lead, this year we also get puppies!

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance for the Tandem Mobi insulin pump for people with diabetes age 6 and up, expanding the company’s portfolio of products. The Tandem Mobi is fully controllable from a mobile app and is the world’s smallest durable automated insulin delivery system.

A recent study published in The Lancet reveals that the global prevalence of diabetes is expected to more than double in the next 30 years, affecting over 1.3 billion people worldwide. Currently, over half a billion people are living with diabetes, with a global prevalence rate of 6.1%. Diabetes is identified as one of the top 10 leading causes of death and disability globally. The study highlights regional variations, with the highest rates found in North Africa and the Middle East. Additionally, the research emphasizes that almost all cases (96%) are type 2 diabetes (T2D), with high body mass index (BMI) being the primary risk factor. The study emphasizes the complex nature of diabetes prevention and control, involving genetic, logistical, social, and financial factors. The findings stress the need for a comprehensive understanding of diabetes impact at a granular level to address disparities and improve access to screening and treatment. The study was supported by the Bill & Melinda Gates Foundation.